Johnson & Johnson’s Strong Q3 Performance and Strategic Initiatives Drive Buy Rating
I'm PortAI, I can summarize articles.
Josh Jennings has issued a Buy rating for Johnson & Johnson, citing strong Q3 financial performance that exceeded market expectations in revenue and earnings per share. The company showed growth in its Innovative Medicine and MedTech segments, despite challenges like the loss of exclusivity for Stelara. JNJ has raised its operational sales guidance, indicating confidence in future growth, supported by strategic initiatives, including the planned separation of its orthopedics division. UBS also maintains a Buy rating with a $214 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments